BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Price, Quote, News and Overview
NASDAQ:BIAF - Nasdaq - US09076W1099 - Common Stock - Currency: USD
BIAF Quote, Performance and Key Statistics
0.2921
+0.07 (+29.76%)
The current stock price of BIAF is 0.2921 USD. In the past month the price decreased by -42.73%. In the past year, price decreased by -89.06%.
BIAF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About BIAF
Company Profile
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Company Info
BIOAFFINITY TECHNOLOGIES INC
3300 Nacogdoches Road, Suite 216
San Antonio TEXAS US
Employees: 14
Phone: 12106985334
BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ
What is the stock price of BIOAFFINITY TECHNOLOGIES INC today?
The current stock price of BIAF is 0.2921 USD. The price increased by 29.76% in the last trading session.
What is the ticker symbol for BIOAFFINITY TECHNOLOGIES INC stock?
The exchange symbol of BIOAFFINITY TECHNOLOGIES INC is BIAF and it is listed on the Nasdaq exchange.
On which exchange is BIAF stock listed?
BIAF stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOAFFINITY TECHNOLOGIES INC stock?
6 analysts have analysed BIAF and the average price target is 6.12 USD. This implies a price increase of 1995.17% is expected in the next year compared to the current price of 0.2921. Check the BIOAFFINITY TECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOAFFINITY TECHNOLOGIES INC worth?
BIOAFFINITY TECHNOLOGIES INC (BIAF) has a market capitalization of 5.33M USD. This makes BIAF a Nano Cap stock.
How many employees does BIOAFFINITY TECHNOLOGIES INC have?
BIOAFFINITY TECHNOLOGIES INC (BIAF) currently has 14 employees.
What are the support and resistance levels for BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?
BIOAFFINITY TECHNOLOGIES INC (BIAF) has a support level at 0.29 and a resistance level at 0.34. Check the full technical report for a detailed analysis of BIAF support and resistance levels.
Is BIOAFFINITY TECHNOLOGIES INC (BIAF) expected to grow?
The Revenue of BIOAFFINITY TECHNOLOGIES INC (BIAF) is expected to decline by -36.83% in the next year. Check the estimates tab for more information on the BIAF EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIAF, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIAF, evaluating the profitability, health, valuation and growth aspects
- BIOAFFINITY TECHNOLOGIES INC (BIAF) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOAFFINITY TECHNOLOGIES INC (BIAF) Sales and EPS estimates to see what analysts future expectations are.
- BIOAFFINITY TECHNOLOGIES INC (BIAF) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOAFFINITY TECHNOLOGIES INC (BIAF) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Chart to make your own analysis
- BIOAFFINITY TECHNOLOGIES INC (BIAF) Latest news and press-releases to stay up to date.
Does BIOAFFINITY TECHNOLOGIES INC (BIAF) stock pay dividends?
BIAF does not pay a dividend.
When does BIOAFFINITY TECHNOLOGIES INC (BIAF) report earnings?
BIOAFFINITY TECHNOLOGIES INC (BIAF) will report earnings on 2025-05-20.
What is the Price/Earnings (PE) ratio of BIOAFFINITY TECHNOLOGIES INC (BIAF)?
BIOAFFINITY TECHNOLOGIES INC (BIAF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).
What is the Short Interest ratio of BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?
The outstanding short interest for BIOAFFINITY TECHNOLOGIES INC (BIAF) is 2.2% of its float. Check the ownership tab for more information on the BIAF short interest.
BIAF Technical Analysis
BIAF Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BIAF. BIAF has a bad profitability rating. Also its financial health evaluation is rather negative.
BIAF Financial Highlights
Over the last trailing twelve months BIAF reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 16.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -138.78% | ||
| ROE | -347.42% | ||
| Debt/Equity | 0.18 |
BIAF Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to BIAF. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 45.12% and a revenue growth -36.83% for BIAF